Loading organizations...
Sierra Oncology was a late-stage biopharmaceutical company dedicated to developing targeted therapies for patients with rare forms of cancer, prominently featuring momelotinib for myelofibrosis. The company focused on advancing its pipeline through clinical development, aiming to address significant unmet medical needs in oncology with precision treatments. Its approach centered on identifying specific pathways and mechanisms driving rare cancers to create more effective and less toxic therapeutic options.
The company was founded in 2003 by Mina Patel Sooch and Robert Forgey. Their foundational insight stemmed from the critical need for specialized treatments in underserved oncology indications, recognizing that broad-spectrum approaches often fell short for rare and complex malignancies. Sooch and Forgey brought together a team with deep expertise in drug discovery and development, driven by a commitment to translate scientific understanding into tangible patient benefits.
Sierra Oncology's primary beneficiaries were patients suffering from rare cancers, particularly those with myelofibrosis, who often face limited treatment alternatives. The company's vision was to deliver innovative, targeted medicines that could significantly improve patient outcomes and quality of life. Sierra Oncology aimed to lead the charge in bringing these much-needed therapies from clinical research to those who would benefit most, envisioning a future where rare cancer patients have access to effective and tailored treatment solutions.
Sierra Oncology has raised $60.0M across 1 funding round.
Sierra Oncology has raised $60.0M in total across 1 funding round.
Sierra Oncology has raised $60.0M in total across 1 funding round.
Sierra Oncology's investors include Frazier Healthcare Partners, OrbiMed, Sofinnova Investments, VantagePoint Capital Partners.
Sierra Oncology is not a technology company; it is a late-stage biopharmaceutical company focused on researching, developing, and commercializing targeted therapies for hematology and oncology patients, particularly those with rare cancers. Its lead product candidate, momelotinib, is an oral inhibitor targeting JAK1, JAK2, and ACVR1 for myelofibrosis patients with anemia, addressing unmet needs in symptom relief, splenic response, and transfusion independence. The company also advanced SRA515 (bromodomain inhibitor) and SRA737 (Checkpoint kinase 1 inhibitor), though its primary momentum centered on momelotinib's Phase 3 MOMENTUM trial success in 2022, leading to a New Drug Application submission to the FDA.[1][2][3]
Sierra Oncology served patients with hematologic malignancies and solid tumors, solving problems like anemia in myelofibrosis where existing JAK inhibitors fall short. Growth peaked with positive clinical data but halted upon its acquisition by GSK in 2022 for $1.9 billion, integrating its pipeline into GSK's oncology portfolio.[1][2]
Founded in 2014 as a clinical-stage biotech, Sierra Oncology emerged from the need for precision therapies in oncology, building on prior assets like momelotinib (originally from Gilead). Key figures included CEO David Shook and a team with expertise in hematology drug development; the company spun out to focus on late-stage assets for rare cancers.[2][3]
Early traction came from licensing momelotinib and advancing trials, culminating in the pivotal MOMENTUM Phase 3 trial results presented at ASCO 2022, which met all endpoints and drove acquisition interest. This marked a rapid path from startup to buyout in under a decade.[1][2]
Sierra Oncology rode the wave of precision oncology and synthetic lethality trends, where targeted small molecules address genetically defined cancer subsets amid rising myelofibrosis prevalence (projected 15-20% annual growth due to aging populations).[2] Timing aligned with post-2020 demand for anemia-managing therapies in JAK inhibitor space, fueled by trial successes amid a biotech M&A surge—GSK's acquisition exemplified Big Pharma's strategy to bolster oncology pipelines without full R&D risk.[1][2]
It influenced the ecosystem by validating momelotinib's mechanism, now advancing under GSK toward potential approvals, accelerating innovation in immuno-oncology and cell therapy combinations.[2]
Post-acquisition, Sierra Oncology's assets thrive within GSK's expanded oncology focus, with momelotinib nearing commercialization—GSK filed in Europe by late 2022, targeting FDA approval and launch by 2023-2024. Trends like anemia-centric myelofibrosis therapies and synthetic lethality will propel it, potentially capturing significant market share in a $5B+ space.[2]
Its legacy elevates targeted rare cancer treatments, with GSK likely evolving momelotinib into combo regimens, solidifying impact far beyond standalone biotech constraints—transforming patient outcomes from a focused innovator into a portfolio cornerstone.[1][2]
Sierra Oncology has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series D in April 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2014 | $60.0M Series D | Frazier Healthcare Partners, OrbiMed, Sofinnova Investments, VantagePoint Capital Partners |